



**УКРАЇНА**

**Комунальне некомерційне підприємство  
Львівської обласної ради**

**“Львівський онкологічний регіональний  
лікувально-діагностичний центр”**

79031, м. Львів, вул. Я. Гашека, 2-а

тел. (032) 295-40-80, факс: (032) 295-37-51

The Secretary of the 22nd Expert Committee on the Selection and Use of  
Essential Medicines

Department of Essential Medicines and Health Products (EMP)

World Health Organization (WHO)

20 Avenue Appia

CH-1211 Geneva 27 Switzerland

Dear Committee Members,

Our clinic treats more than 1,000 breast cancer patients every year. We have experience in international clinical trials since 1999 (over 200 clinical trials). Our center participated in 6 clinical trials with perzumab in adjuvant, neoadjuvant and palliative regimens (BO25126, MO28047, BO28407, BO28408, WO40324, MO29406). Some of our patients receive targeted therapy (trastuzumab + pertuzumab) in routine treatment. In our clinical material we confirm the high efficiency of this drug. Here is just one example. Patient M since 04.03.14, has already received 125 cycles of trastuzumab + pertuzumab. She continues treatment.

We asked the Ministry of Health of Ukraine to include pertuzumab in the list of essential drugs for breast cancer. We support the inclusion of pertuzumab to the 23rd Edition of the WHO Essential Medicines List (EML) 2021.

Best regards,

Yaroslav Shparyk, MD, PhD

Head of Dept Medical Oncology

Communal nonprofit enterprise of Lviv regional district “Lviv regional oncology  
medical diagnostic centre”

yshparyk@ukr.net

21 May 2021